3-methylcholanthrene has been researched along with simvastatin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CC; Chou, HC; Hsu, YH; Juan, SH; Lee, YG | 1 |
| Chang, CC; Hsu, SP; Huang, KH; Juan, SH; Lee, YG; Sue, YM | 1 |
2 other study(ies) available for 3-methylcholanthrene and simvastatin
| Article | Year |
|---|---|
3-Methylcholanthrene/Aryl-Hydrocarbon Receptor-Mediated Hypertension Through eNOS Inactivation.
Topics: Animals; Cerebrum; Down-Regulation; Endothelial Cells; Hypertension; Methylcholanthrene; Mice; Models, Biological; Nitric Oxide; Nitric Oxide Synthase Type III; Nitroprusside; Protein Binding; Proto-Oncogene Proteins c-akt; Receptors, Aryl Hydrocarbon; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin; Time Factors | 2017 |
Simvastatin reduces the carcinogenic effect of 3-methylcholanthrene in renal epithelial cells through histone deacetylase 1 inhibition and RhoA reactivation.
Topics: Carcinogenesis; Cells, Cultured; Epithelial Cells; Epithelial-Mesenchymal Transition; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Hyaluronan Receptors; Hydroxamic Acids; Kidney; Methylcholanthrene; Receptors, Aryl Hydrocarbon; rhoA GTP-Binding Protein; Simvastatin | 2019 |